We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.67%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$666M
AUM Growth
-$78.6M
(-11%)
Cap. Flow
+$47.8M
Cap. Flow
% of AUM
7.17%
Top 10 Holdings %
Top 10 Hldgs %
3.73%
Holding
1,985
New
628
Increased
360
Reduced
345
Closed
644
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$3.83M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$3M |
| 3 |
Teck Resources
TECK
|
+$2.87M |
| 4 |
MODV
ModivCare
MODV
|
+$2.67M |
| 5 |
Genpact
G
|
+$2.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.07M |
| 2 |
CHS
Chicos FAS, Inc.
CHS
|
+$2.68M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$2.45M |
| 4 |
Crane NXT
CXT
|
+$2.44M |
| 5 |
ATCO
Atlas Corp.
ATCO
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.12% |
| 2 | Technology | 15.11% |
| 3 | Consumer Discretionary | 12.76% |
| 4 | Industrials | 12.53% |
| 5 | Financials | 11.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Puma Biotechnology
PBYI
$454M
| $196K | 0.03% |
68,749
-70,194
| -51% | -$175K |
|
|
ATNX
1077
DELISTED
Athenex, Inc. Common Stock
ATNX
| $195K | 0.03% |
23,827
+12,235
| +106% | +$137K |
|
1078
GoodRx Holdings
GDRX
$1.26B
| $194K | 0.03% |
+32,755
| New | +$365K |
|
|
B
1079
Barrick Mining
B
$73.2B
| $193K | 0.03% |
10,920
-27,783
| -72% | -$603K |
|
|
KNBE
1080
DELISTED
KnowBe4, Inc. Class A Common Stock
KNBE
| $193K | 0.03% |
+12,378
| New | +$242K |
|
|
REE
1081
DELISTED
REE Automotive
REE
| $192K | 0.03% |
+5,512
| New | +$282K |
|
1082
TG Therapeutics
TGTX
$7.62B
| $192K | 0.03% |
45,281
-17,903
| -28% | -$112K |
|
1083
Prelude Therapeutics
PRLD
$390M
| $191K | 0.03% |
36,626
+13,425
| +58% | +$68.3K |
|
1084
Vital Farms
VITL
$525M
| $190K | 0.03% |
21,739
+10,129
| +87% | +$108K |
|
1085
Kratos Defense & Security Solutions
KTOS
$11.4B
| $189K | 0.03% |
13,601
-6,632
| -33% | -$103K |
|
1086
Interface
TILE
$2.22B
| $188K | 0.03% |
15,029
-4,902
| -25% | -$65K |
|
|
SLGC
1087
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $188K | 0.03% |
+41,618
| New | +$248K |
|
1088
Lineage Cell Therapeutics
LCTX
$278M
| $187K | 0.03% |
118,308
+45,802
| +63% | +$60.4K |
|
|
UPH
1089
DELISTED
UpHealth, Inc.
UPH
| $185K | 0.03% |
31,241
-12,237
| -28% | -$95.2K |
|
1090
AXT Inc
AXTI
$5.8B
| $184K | 0.03% |
31,394
+10,444
| +50% | +$61.5K |
|
1091
Duluth Holdings
DLTH
$159M
| $184K | 0.03% |
+19,316
| New | +$225K |
|
1092
CBAK Energy Technology Ltd
CBAT
$57.8M
| $183K | 0.03% |
170,836
+39,622
| +30% | +$45.9K |
|
1093
Gossamer Bio
GOSS
$87M
| $183K | 0.03% |
21,822
+2,115
| +11% | +$16.4K |
|
|
CBAY
1094
DELISTED
Cymabay Therapeutics
CBAY
| $183K | 0.03% |
62,194
-130,050
| -68% | -$311K |
|
1095
RadNet
RDNT
$5.69B
| $182K | 0.03% |
10,546
-9,683
| -48% | -$188K |
|
|
SCWX
1096
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $181K | 0.03% |
16,662
-579
| -3% | -$6.58K |
|
|
PETQ
1097
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $181K | 0.03% |
+10,760
| New | +$197K |
|
1098
Absci
ABSI
$1.51B
| $179K | 0.03% |
+53,983
| New | +$268K |
|
|
BRDG
1099
DELISTED
Bridge Investment Group
BRDG
| $179K | 0.03% |
+12,278
| New | +$218K |
|
1100
Atea Pharmaceuticals
AVIR
$420M
| $178K | 0.03% |
+25,080
| New | +$171K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, GSA Capital Partners held 1,985 positions worth $666M, down 11% from $745M the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.
GSA Capital Partners deployed $47.8M of net new capital in Q2 2022, opening 628 new positions and adding to 360 existing holdings. Its largest new stake was Relay Therapeutics: 178,593 shares worth $2.99M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Chicos FAS, Inc., an estimated $2.68M trimmed.
- GSA Capital Partners's largest Q2 2022 buy was Relay Therapeutics: 178,593 shares worth $2.99M.
- GSA Capital Partners added most to Genpact in Q2 2022, an estimated $2.6M increase.
- GSA Capital Partners's biggest Q2 2022 reduction was Chicos FAS, Inc., cutting an estimated $2.68M.
- GSA Capital Partners fully exited Amazon in Q2 2022, selling an estimated $3.07M.
- GSA Capital Partners's ten largest holdings make up 3.7% of its $666M portfolio in Q2 2022.
- GSA Capital Partners opened 628 new positions and closed 644 in Q2 2022.
- GSA Capital Partners's portfolio value fell 11% quarter-over-quarter to $666M.
Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.